Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)

NCT00472927 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Postmenopause

Interventions

DRUG: Premarin/MPA 0.45 mg/1.5 mg

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer